Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Other Accumulated Expenses (2016 - 2025)

Fate Therapeutics' Other Accumulated Expenses history spans 12 years, with the latest figure at $4.4 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 30.62% year-over-year to $4.4 million; the TTM value through Dec 2025 reached $4.4 million, down 30.62%, while the annual FY2025 figure was $4.4 million, 30.62% down from the prior year.
  • Other Accumulated Expenses reached $4.4 million in Q4 2025 per FATE's latest filing, up from $3.9 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $19.2 million in Q4 2022 to a low of $3.9 million in Q3 2025.
  • Average Other Accumulated Expenses over 5 years is $9.9 million, with a median of $8.4 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: surged 183.19% in 2021, then crashed 63.72% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $11.7 million in 2021, then soared by 63.75% to $19.2 million in 2022, then tumbled by 57.66% to $8.1 million in 2023, then dropped by 21.67% to $6.4 million in 2024, then plummeted by 30.62% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Other Accumulated Expenses are $4.4 million (Q4 2025), $3.9 million (Q3 2025), and $4.9 million (Q2 2025).